EUVIMEDEUVIMED entdecken
FallberichtOpen Access · CC BY 4.0

First‐Line Treatment of Icaritin and Thalidomide in a Patient With Hepatocellular Carcinoma With PR : A Case Report

Zaiyong Jin, Fei Zhou, Zhuo Wang, Hongji Li iD

Cancer Reports · 2025

DOI: 10.1002/cnr2.70136 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Cancer Reports, 2025. Verfasst von Zaiyong Jin und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hepatological Surgery, Jilin City Central Hospital, Jilin, China. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms, Thalidomide, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Hepatocellular carcinoma (HCC) remains a significant global health burden, with unmet clinical needs despite the availability of multiple therapeutic options. Case We present the case of an 85‐year‐old male diagnosed with HCC and bilateral lung metastases following hepatectomy. The patient responded favorably to treatment with icaritin and thalidomide, which resulted in a reduction in alpha‐fetoprotein (AFP) levels and tumor size. This treatment achieved partial remission, with a progression‐free survival (PFS) of 24 months and an overall survival (OS) of 33 months. Unfortunately, the patient ultimately passed away due to a cerebral infarction unrelated to cancer progression.

Conclusion

This case underscores the potential of icaritin as a therapeutic option for HCC patients with compromised health status. The combination of icaritin and thalidomide demonstrated promising efficacy in this real‐world scenario. Multidisciplinary combination treatment strategies incorporating icaritin merit further exploration, given its immunomodulatory effects and favorable safety profile.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, HepatocellularLiver NeoplasmsThalidomideAntineoplastic Combined Chemotherapy ProtocolsFlavonoidsLung NeoplasmsHumansMaleAged, 80 and overalpha-FetoproteinsHepatectomyFatal Outcome

Stichwörter der Autor:innen

combination therapyicaritinlate‐stage hepatocellular carcinomapartial remissionthalidomide (TLD)

Substanzen

ThalidomideicaritinFlavonoidsalpha-Fetoproteins

Autor:innen und Institutionen

  • Department of Hepatological Surgery, Jilin City Central Hospital, Jilin, China.
  • Medical Image Central, Jilin City Central Hospital, Jilin, China.
  • Department of Abdominal Imaging Diagnostic, Jilin City Central Hospital, Jilin, China.
  • Department of Traditional and Western Oncology, Jilin City Central Hospital, Jilin, China.

ORCID-Profile: Hongji Li

Zitieren

APA

Jin, Z., Zhou, F., Wang, Z., & Li, H. (2025). First‐Line Treatment of Icaritin and Thalidomide in a Patient With Hepatocellular Carcinoma With PR : A Case Report. Cancer Reports. https://doi.org/10.1002/cnr2.70136

Vancouver

Jin Z, Zhou F, Wang Z, Li H. First‐Line Treatment of Icaritin and Thalidomide in a Patient With Hepatocellular Carcinoma With PR : A Case Report. Cancer Reports. 2025. doi:10.1002/cnr2.70136

BibTeX
@article{Jin2025,
  author = {Jin, Zaiyong and Zhou, Fei and Wang, Zhuo and Li, Hongji},
  title = {First‐Line Treatment of Icaritin and Thalidomide in a Patient With Hepatocellular Carcinoma With PR : A Case Report},
  journal = {Cancer Reports},
  year = {2025},
  doi = {10.1002/cnr2.70136}
}
Kostenlos starten →